Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN PF 10 versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN PF 10 versus TRAVASOL 2 75 IN DEXTROSE 15 IN PLASTIC CONTAINER.
AMINOSYN-PF 10% vs TRAVASOL 2.75% IN DEXTROSE 15% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn-PF 10% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in neonates and pediatric patients.
Travasol 2.75% in Dextrose 15% is a parenteral nutrition solution. Travassol provides amino acids for protein synthesis, while dextrose provides caloric energy. The mechanism involves intravenous administration to bypass gastrointestinal absorption, directly delivering substrates for metabolism and tissue repair.
Intravenous infusion: 1-1.5 g amino acids/kg/day (protein equivalent) as part of total parenteral nutrition. Typical rate: 0.5-2.0 mL/kg/hour initially, titrated to metabolic needs.
Intravenous infusion: 1000-2000 mL/day (providing 27.5 g amino acids and 150 g dextrose) at a rate not exceeding 4 mL/kg/hour.
None Documented
None Documented
Variable; amino acids have half-lives of minutes to hours; clinical context: continuous infusion maintains steady state
Not applicable as a direct drug; components have variable half-lives: amino acids are rapidly cleared (minutes to hours), dextrose is regulated by insulin (glucose half-life ~1-2 hours in euglycemia).
Renal: >90% as amino acids and metabolites; <10% fecal/biliary
Travasol 2.75% in dextrose 15% is a parenteral nutrition solution. The amino acids are metabolized and their nitrogen is primarily excreted as urea in urine (renal >90%), with minimal biliary or fecal elimination. Dextrose is metabolized to CO2 and water, exhaled via lungs and excreted renally.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution